| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.21 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
A presente dissertação está integrada na unidade curricular “Estágio”, do Mestrado
Integrado em Ciências Farmacêuticas. Este trabalho é composto por duas
componentes: a componente de investigação (Capítulo I) e a componente profissional
em farmácia comunitária (Capítulo II).
O primeiro capítulo corresponde à revisão da literatura sobre os efeitos farmacológicos
em ensaios pré-clínicos do 10ß,17ß-dihidroxiestra-1,4-dien-3-ona, 10ß,17adihidroxiestra-1,4-dien-3-ona e 10ß-hidroxiestra-1,4-dieno-3,17-diona, que são prófármacos do estradiol, 17a-estradiol e estrona, respetivamente. O 10ß,17ßdihidroxiestra-1,4-dien-3-ona originou um melhor desempenho no teste
comportamental RAWN e uma redução dos níveis de Aß, no contexto da doença de
Alzheimer; atenuou o aumento da temperatura da pele da cauda, em afrontamentos; e,
foi metabolizado em estradiol na retina, no contexto do glaucoma. O 10ß,17adihidroxiestra-1,4-dien-3-ona reduziu os tempos de imobilidade no teste de natação de
Porsolt, apresentado, assim, atividade antidepressiva. O 10ß,17ß-dihidroxiestra-1,4-
dien-3-ona e o 10ß,17a-dihidroxiestra-1,4-dien-3-ona não apresentaram os efeitos
secundários periféricos associados aos estrogénios, sendo, assim, potenciais candidatos
a terapêuticas estrogénicas seguras e eficazes nas doenças acima referidas. O 10ßhidroxiestra-1,4-dieno-3,17-diona apresentou efeitos anti-proliferativos em seis linhas
celulares (MCF-7, T47-D, LNCaP, HepaRG, Caco-2 e NHDF), principalmente contra as
células cancerígenas hormono-dependentes (MCF-7, T47-D e LNCaP).
O segundo capítulo é referente ao estágio curricular em farmácia comunitária, na
Farmácia Queija Ferreira, no Porto. Durante o estágio, tive a oportunidade de colocar
em prática os conhecimentos técnico-científicos adquiridos no mestrado integrado e, de
melhorar as minhas competências interpessoais.
This dissertation is part of the curricular unit “Internship”, of the Integrated Master in Pharmaceutical Sciences. This work consists in two components: the research component (Chapter I) and the professional component in community pharmacy (Chapter II). The first chapter corresponds to the literature review about the pharmacological effects in preclinical trials of 10ß,17ß-dihydroxyestra-1,4-dien-3-one, 10ß,17a-dihydroxyestra1,4-dien-3-one and 10ß-hydroxyestra-1,4-diene-3,17-dione, which are prodrugs of estradiol, 17a-estradiol and estrone, respectively. The 10ß,17ß-dihydroxyestra-1,4-dien3-one resulted in a better performance in the RAWN behavioral test and a reduction in Aß levels, in the context of Alzheimer's disease; attenuated the increase in tail skin temperature in hot flashes; and, was metabolized to estradiol in the retina, in the context of glaucoma. The 10ß,17a-dihydroxyestra-1,4-dien-3-one reduced immobility times in the Porsolt swimming test, thus showing antidepressant activity. The 10ß,17ßdihydroxyestra-1,4-dien-3-one and the 10ß,17a-dihydroxyestra-1,4-dien-3-one did not show the peripheral side effects associated with estrogens, thus being potential candidates for safe and effective estrogenic therapies in the diseases mentionated above. 10ß-hydroxyestra-1,4-diene-3,17-dione showed anti-proliferative effects in six cell lines (MCF-7, T47-D, LNCaP, HepaRG, Caco-2 and NHDF), mainly against cancer cells hormone-dependent (MCF-7, T47-D and LNCaP). The second chapter refers to the curricular internship in community pharmacy, at Farmácia Queija Ferreira, in Porto. During the internship. I had the opportunity to put into practice the technical-scientific knowledge acquired in the integrated master's degree and to improve my interpersonal skills.
This dissertation is part of the curricular unit “Internship”, of the Integrated Master in Pharmaceutical Sciences. This work consists in two components: the research component (Chapter I) and the professional component in community pharmacy (Chapter II). The first chapter corresponds to the literature review about the pharmacological effects in preclinical trials of 10ß,17ß-dihydroxyestra-1,4-dien-3-one, 10ß,17a-dihydroxyestra1,4-dien-3-one and 10ß-hydroxyestra-1,4-diene-3,17-dione, which are prodrugs of estradiol, 17a-estradiol and estrone, respectively. The 10ß,17ß-dihydroxyestra-1,4-dien3-one resulted in a better performance in the RAWN behavioral test and a reduction in Aß levels, in the context of Alzheimer's disease; attenuated the increase in tail skin temperature in hot flashes; and, was metabolized to estradiol in the retina, in the context of glaucoma. The 10ß,17a-dihydroxyestra-1,4-dien-3-one reduced immobility times in the Porsolt swimming test, thus showing antidepressant activity. The 10ß,17ßdihydroxyestra-1,4-dien-3-one and the 10ß,17a-dihydroxyestra-1,4-dien-3-one did not show the peripheral side effects associated with estrogens, thus being potential candidates for safe and effective estrogenic therapies in the diseases mentionated above. 10ß-hydroxyestra-1,4-diene-3,17-dione showed anti-proliferative effects in six cell lines (MCF-7, T47-D, LNCaP, HepaRG, Caco-2 and NHDF), mainly against cancer cells hormone-dependent (MCF-7, T47-D and LNCaP). The second chapter refers to the curricular internship in community pharmacy, at Farmácia Queija Ferreira, in Porto. During the internship. I had the opportunity to put into practice the technical-scientific knowledge acquired in the integrated master's degree and to improve my interpersonal skills.
Description
Keywords
10ß 10ß-Hidroxiestra-1 17-Diona 17a-Dihidroxiestra-1 17ß-Dihidroxiestra-1 4-Dien-3-Ona 4-Dieno-3 Farmácia Comunitária